Biotech Eiger Can Sell Rare-Disease Drug For $46M In Ch. 11
Insolvent biotechnology company Eiger BioPharmaceuticals Inc. received approval Tuesday at a hearing in Texas to sell its drug treatment for a rare genetic disorder to Sentynl Therapeutics, a subsidiary of Indian drugmaker Zydus...To view the full article, register now.
Already a subscriber? Click here to view full article